Jazz Pharmaceuticals Plc Stock Price, News & Analysis

Stand Up To Cancer, in partnership with Jazz Pharmaceuticals, has launched a new public service announcement (PSA) to raise awareness about small cell lung cancer, particularly in Black and Hispanic communities. The PSA, available in both English and Spanish, focuses on the importance of early screening to improve survival rates, as these communities face significant disparities in diagnosis. Jazz is also supporting SU2C's Catalyst program, which funds research for new treatments in oncology.

Jazz Pharmaceuticals reported its Q3 2022 financial results, achieving total revenues of $940.7 million, a 12% increase year-over-year. The company raised its 2022 revenue guidance mid-point to $3.65 billion. Key performance drivers included strong adoption of Xywav and Epidiolex, with Xywav sales up 67% to $255.9 million. The company continues to expand its pipeline with new clinical trials, including JZP815 and suvecaltamide. Despite a GAAP net loss of $19.6 million, adjusted net income rose to $370.4 million.

On November 3, 2022, Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the presentation of 13 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 10-13, 2022. The research will feature findings on Rylaze^®, Vyxeos^®, and Defitelio^®. Notable highlights include a Phase 2/3 trial demonstrating the efficacy and safety of intravenous Rylaze in patients with Acute Lymphoblastic Leukemia. Jazz emphasized its commitment to advancing oncology solutions for patients with rare forms of leukemia.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in three investor conferences this November. The Jefferies London Healthcare Conference is on November 15, 2022 at 5:20 a.m. ET. The 5th Annual Evercore ISI HealthCONx Conference follows on November 29, 2022 at 1:50 p.m. ET. Finally, the Piper Sandler 34th Annual Healthcare Conference will occur on November 30, 2022 at 12:00 p.m. ET. Audio webcasts of the presentations will be available on their website, archived for 30 days.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will disclose its 2022 Q3 financial results on November 9, 2022, after U.S. market close. A live audio webcast will follow at 4:30 p.m. ET, providing an analysis of the results along with a business update. Interested participants are encouraged to register ahead of time for the event. Jazz Pharmaceuticals focuses on developing transformative medicines in neuroscience and oncology for patients with serious diseases, and it operates in nearly 75 countries.

Zymeworks announced an exclusive licensing agreement with Jazz Pharmaceuticals for its HER2-targeted bispecific antibody, zanidatamab. Zymeworks is set to receive an upfront payment of $50 million, with future payments potentially reaching $1.76 billion based on regulatory and commercial milestones. The licensing covers key markets, including the U.S., Europe, and Japan. A conference call will take place today at 8:00 am EST to discuss the partnership and its implications for clinical development.

Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody, from Zymeworks in major markets including the U.S., Europe, and Japan. Zymeworks will receive an upfront payment of $50 million, with the potential for total payments reaching $1.76 billion upon meeting various milestones. Zanidatamab, currently in pivotal trials for HER2-expressing biliary tract cancer and gastroesophageal adenocarcinoma, has received Breakthrough Therapy designation from the FDA, underscoring its potential in oncology.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is set to present seven abstracts at the 35th annual Psych Congress 2022 from September 17-20. The presentations highlight Jazz's leadership in sleep medicine, showcasing research on Xywav, a lower-sodium oxybate approved for treating narcolepsy and idiopathic hypersomnia. Key data include efficacy results from studies like TENOR and SEGUE, focusing on narcolepsy patients transitioning to Xywav. Jazz's commitment to innovation is underscored by its FDA-approved therapies, enhancing options for patients with debilitating sleep disorders.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in two upcoming investor conferences in September 2022. The Citi's 17th Annual BioPharma Conference is scheduled for September 7, 2022, at 1:00 p.m. ET. The Wells Fargo Healthcare Conference will follow on September 8, 2022, at 11:00 a.m. ET. Audio webcasts of both presentations will be available on the Jazz Pharmaceuticals website and will be archived for 30 days.